Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients between the ages of 18 and 65 years, inclusive;~2. Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the MINI and meets all of the following criteria:~   1. The start of the current major depressive episode (MDE) is at least 8 weeks but not more than 18 months prior to Screening;~  2. Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;~  3. Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening (Visit 1) and at Baseline;~  4. Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;~  5. Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.~3. Currently having an inadequate response to ADT (less than 50% improvement) as confirmed by the Investigator and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:~   1. citalopram/escitalopram~  2. fluoxetine~  3. paroxetine~  4. sertraline~  5. duloxetine~  6. levomilnacipran/milnacipran (if locally approved for MDD)~  7. venlafaxine/desvenlafaxine~  8. bupropion~  9. vilazodone~  10. vortioxetine~Exclusion Criteria:~1. Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:~   1. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;~  2. Bipolar Disorder;~2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:~   1. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses.~  2. Eating disorder;~  3. Substance use disorders (excluding nicotine);~  4. Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;~  5. Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;~3. The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;~4. The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;~5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:~   1. At Screening, the patient scores yes on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores yes on Suicidal Ideation Items 4 or 5 since the Screening Visit;~  2. At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;~  3. At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or~  4. The patient is considered to be in imminent danger to him/herself or others.~6. The patient has a first MDE at age 60 years or older.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lumateperone 42 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).